drugset / Trial / NCT00777478
Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.
Timeline
- Start
- 2008-12
- Primary completion
- 2012-05
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Sunitinib | Small molecule | — | — |